Cardiovascular Journal of Africa: Vol 32 No 6 (NOVEMBER/DECEMBER 2021)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 32, No 6, November/December 2021 AFRICA 335 gained with this anti-arrhythmic unequivocally recommends it for conversion to SR and maintaining normal rhythm in patients with AF. Moreover, knowledge of the pharmacokinetics and pharmacodynamics of this anti-arrhythmic, along with an understanding of the pathophysiological mechanisms behind AF, provides an additional rationale for early use of amiodarone to prevent long-term complications of AF. References 1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al . 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38): 2893–2962. 2. Di Carlo A, Bellino L, Consoli D, Mori F, Zaninelli A, Baldereschi M, et al . Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: The FAI Project. Europace 2019; 21 (10): 1468–1475. 3. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation – Pharmacological intervention in atrial fibrillation (PIAF): A randomised trial. Lancet 2000; 356 (9244): 1789–1794. 4. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The strategies of treatment of atrial fibrillation (STAF) study. J Am Coll Cardiol 2003; 41 (10): 1690–1696. 5. Hagens VE, Van Gelder IC, Crijns HJGM. The RACE study in perspec- tive of randomized studies on management of persistent atrial fibrilla- tion. Card Electrophysiol Rev 2003; 7 (2): 118–121. 6. Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow- up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004; 109 (16): 1973–1980. 7. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kapłon B, Kołodziej P, et al . Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The results of the Polish how to treat chronic atrial fibrillation (HOT CAFE) study. Chest 2004; 126 (2): 476–486. 8. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22 (2): 240–254. 9. Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 10th edn. Philadelphia, PA: Elsevier/Saunders, 2015. 10. Adams PC, Holt DW, Storey GCA, Morley AR, Callaghan J, Campbell RW. Amiodarone and its desethyl metabolite: Tissue distribution and morphologic changes during long-term therapy. Circulation 1985; 72 (5): 1064–1075. 11. Podrid PJ. Amiodarone: Reevaluation of an old drug. Ann Intern Med 1995; 122 (9): 689–700. 12. Lafuente-Lafuente C, Alvarez JC, Leenhardt A, Mouly S, Extramiana F, Caulin C, et al . Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. Br J Clin Pharmacol 2009; 67 (5): 511–519. 13. Weiss M. The anomalous pharmacokinetics of amiodarone explained by nonexponential tissue trapping. J Pharmacokinet Biopharm 1999; 27 (4): 383–396. 14. Singh BN. Amiodarone: Electropharmacologic Properties . Heidelberg, Berlin: Springer, 1989. 15. Deng P, You T, Chen X, Yuan T, Huang H, Zhong D. Identification of amiodarone metabolites in human bile by ultraperformance liquid chro- matography/quadrupole time-of-flight mass spectrometry. Drug Metab Dispos 2011; 39 (6): 1058–1069. 16. Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol 1991; 31 (11): 1061–1069. 17. Van Erven L, Schalij MJ. Amiodarone: An effective antiarrhythmic drug with unusual side effects. Heart 2010; 96 : 1593–1600. 18. Greenberg ML, Lerman BB, Shipe JR, Kaiser DL, DiMarco JP. Relation between amiodarone and desethylamiodarone plasma concen- trations and electrophysiologic effects, efficacy and toxicity. J Am Coll Cardiol 1987; 9 (5): 1148–1155. 19. Rotmensch HH, Belhassen B, Swanson BN, Shoshani D, Spielman SR, Greenspon AJ, et al. Steady-state serum amiodarone concentrations: Relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med 1984; 101 (4): 462–469. 20. Saksena S, Rothbart ST, Shah Y, Cappello G. Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia. Am J Cardiol 1984; 54 (3): 347–352. 21. Allessie MA. Atrial electrophysiologic remodeling: Another vicious circle? J Cardiovasc Electrophysiol 1998: 1378–1393. 22. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54 : 230–246. 23. Stanley N, Brett B, Dobromir D. Atrial remodeling and atrial fibrilla- tion. Circ Arrhythmia Electrophysiol 2008; 1 (1): 62–73. 24. Dobrev D, Graf E, Wettwer E, Himmel HM, Hála O, Doerfel C, et al . Molecular basis of downregulation of G-protein-coupled inward recti- fying K+ current (ik,ach) in chronic human atrial fibrillation decrease in GIRK4 mrna correlates with reduced IK,ACh and muscarinic receptor- mediated shortening of action potentials. Circulation 2001; 104 (21): 2551–2557. 25. Filgueiras-Rama D, Martins RP, Mironov S, Yamazaki M, Calvo CJ, Ennis SR, et al. Chloroquine terminates stretch-induced atrial fibril- lation more effectively than flecainide in the sheep heart. Circ Arrhyth Electrophysiol 2012; 5 (3): 561–570. 26. Gómez R, Caballero R, Barana A, Amorós I, De Palm S-H, Matamoros M, et al . Structural basis of drugs that increase cardiac inward rectifier Kir2.1 currents. Cardiovasc Res 2014; 104 (2): 337–346. 27. Koivumäki JT, Seemann G, Maleckar MM, Tavi P. In silico screening of the key cellular remodeling targets in chronic atrial fibrillation. PLoS Comput Biol 2014; 10 (5). 28. Sánchez C, Corrias A, Bueno-Orovio A, Davies M, Swinton J, Jacobson I, et al . The Na + K + pump is an important modulator of refractoriness and rotor dynamics in human atrial tissue. Am J Physiol Heart Circ Physiol 2012; 302 (5): H1146. 29. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrilla- tion. Circ Res 1997; 81 (4): 512–525. 30. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997; 35 (1): 13–29. 31. Zapolski T, Wysoki ń ski A. Stunning of the left atrium after pharmaco- logical cardioversion of atrial fibrillation. Kardiol Pol 2005; 63 (3): 254. 32. Dobrev D, Nattel S. Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J Cardiovasc Pharmacol 2008; 52 (4): 293–299. 33. Dobrev D, Voigt N, Wehrens XHT. The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications. Cardiovasc Res 2011; 89 (4): 734–743. 34. Grandi E, Pandit SV, Voigt N, Workman AJ, Dobrev D, Jalife J, et al . Human atrial action potential and Ca 2+ model: Sinus rhythm and chronic atrial fibrillation . Circ Res 2011; 109 (9): 1055–1066. 35. Christ T, Boknik P, Wöhrl S, Wettwer E, Graf EM, Bosch RF, et al . L-type Ca 2+ current downregulation in chronic human atrial fibrillation